Not all sufferers with CLL demand therapy. Inspite of all the latest improvements, the iwCLL even now suggests watchful observation for patients with asymptomatic disease.86 This advice is predicated on not less than two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).